Edwards Lifesciences CEO Bernard Zovighian Sells Shares

On June 17, 2026, Bernard Zovighian, the CEO of Edwards Lifesciences Corporation, sold 523 shares of the company. This planned transaction was executed at an average price of $87.92 per share, totaling approximately $45,982.

Insider Buying and Selling at Edwards Lifesciences Corporation

In addition to Bernard Zovighian's planned sale, other recent insider activities at Edwards Lifesciences included Andrew Dahl, SVP and Corporate Controller, who sold 568 shares on May 29, 2026, at $86.08 per share. Donald Bobo Jr., CVP of Strategy/Corp Development, sold 23,145 shares on May 27, 2026, at $86.42 per share. Daveen Chopra, CVP of TMTT & Surgical, sold 1,500 shares on May 22, 2026, at $84.60 per share. Daniel Lippis, CVP of TAVR, bought 620 shares on May 18, 2026, at $72.68, and later sold the same amount.

Other Institutional Activity in Edwards Lifesciences

BlackRock, Inc. increased its holdings in Edwards Lifesciences by 129,018 shares, ending with a total of 52,590,933 shares valued at about $4.21 billion. Vanguard Capital Management LLC made a new investment, acquiring 37,727,792 shares worth approximately $3.02 billion. Vanguard Portfolio Management LLC followed suit, adding 26,407,018 shares valued at $2.11 billion. State Street Corp boosted its stake by 304,875 shares, reaching a total of 26,296,399 shares worth $2.11 billion. Meanwhile, Wellington Management Group LLP added 217,152 shares to hold 22,011,101 shares valued at $1.76 billion. In contrast, JPMorgan Chase & Co reduced its holdings by 4,280,140 shares, now holding 21,744,712 shares worth about $1.73 billion.

Edwards Lifesciences Stock Snapshot

Shares of NYSE:EW traded near $88.58, reflecting a robust market cap of approximately $51 billion. The company has a P/E ratio of 47.9 and a forward P/E of 26.3, indicating expectations of future earnings growth. With a beta of 0.866, Edwards Lifesciences shows lower volatility compared to the overall market. The stock's 52-week range is between $72.30 and $89.60, with a 50-day moving average of $83.03 and a 200-day average of $81.91. The firm's financial health is underscored by a current ratio of 4.42 and a quick ratio of 3.30, with a low debt-to-equity ratio of 6.81.

Recent Earnings

In its recent earnings report, Edwards Lifesciences posted revenue of approximately $6.30 billion, reflecting a revenue growth of 16.7%. The company's net margin stood at 17.39%, while return on equity was 10.46%. Earnings per share were reported at $1.85. Looking ahead, the company is expected to release its next earnings report on July 23, 2026.

Analysts Set New Price Targets

On June 16, 2026, RBC Capital reiterated its 'buy' rating for Edwards Lifesciences, setting a price target of $100. TD Cowen maintained a 'buy' rating with a target of $104 on June 2, 2026. Barclays also maintained its 'buy' rating, targeting $110 on April 27, 2026. The consensus among analysts is a 'buy' recommendation, with an average target price of approximately $96.92, based on 26 analyst opinions.

About Edwards Lifesciences

Edwards Lifesciences Corporation, headquartered in Irvine, California, specializes in medical devices. The company focuses on products and technologies for treating advanced cardiovascular diseases globally. Its offerings include transcatheter heart valve replacement products, such as the Edwards SAPIEN system, and repair solutions for mitral and tricuspid valve diseases. Edwards Lifesciences distributes its products through direct sales and independent distributors.

Bottom Line

The recent insider sale by CEO Bernard Zovighian highlights ongoing activity within Edwards Lifesciences. Investors often track such movements for insights into company leadership's views. With a solid market position and analyst support, Edwards Lifesciences remains a key player in the medical devices sector. Keep in mind that insider transactions are disclosed after the fact and may not reflect current positions.